We are international

Sydney 2005:
Lenalidomide (CC-5013, Revlimid™) and Other IMiDs
By Donna Weber, MD

Dr. Donna Weber discussed lenalidomide (CC-5013, RevlimidTM) and other IMIDS. She reviewed the benefits and limitations of thalidomide therapy to establish the rationale for the development of lenalidomide. In a Phase 2 clinical trial comparing 15mg bid and 30 mg qd lenalidomide, 24% of patients in both treatment groups responded; switching to once-daily dosing minimized side effects. In a large international study in RR MM patients who received 3 prior treatments, lenalidomide and dexamethasone were administered for 4 courses of treatment or until progression of disease. The majority of patients in this trial had stage 3 disease and one third had bone marrow involvement. Lenalidomide showed better responses than lenalidomide + dexamethasone or dexamethasone monotherapy. A 5-fold higher response was seen with lenalidomide + dexamethasone. Common toxicities were present throughout the study; thromboembolic events were more frequent in the North American centers than in the European centers. A study investigating the effects of lenalidomide + dexamethasone in patients previously untreated for MM is enrolling patients. Preliminary results are strong, showing a complete response (CR)/partial response (PR) of 85% and expected manageable toxicities. Dr. Weber ended her presentation by identifying future trials planned for lenalidomide therapy.

Back to session summary

 related articles